Ultima-AOD9604 5mg

MANUFACTURER Ultima Pharmaceuticals - USA
WAREHOUSE USA Warehouse 5
SUBSTANCE AOD 9604 - Anti-Obesity Drug

Your products will be shipped discreetly, without branding, for your privacy and security.

AOD 9604 is a cutting-edge modified form of Growth Hormone, made up of a 191 amino acid peptide. This innovative compound features the final 15 amino acids (positions 176-191) from the Growth Hormone structure, specifically synthesized into a powerful peptide known as GH Frag 176-191, or AOD 9604.

Recognized as one of the most potent peptides for weight loss, AOD 9604 not only promotes fat loss but also supports metabolic enhancement and a host of other benefits.

Gland Stimulated: Pituitary Gland

Key Benefits of AOD 9604:

• Effectively reduces body fat
• Specifically targets and releases fat from obese cells, sparing lean tissues
• Mirrors the natural fat metabolism regulation of growth hormone
• Maintains stable blood sugar levels with no impact on growth
• Stimulates lipolysis, the breakdown of fats
• Inhibits lipogenesis, preventing the conversion of non-fat foods into body fat
• Supports cartilage repair and regeneration, especially when paired with peptide BPC 157.

Mechanism of Action:

AOD-9604, also known as Tyr-hGH Frag 176-191, is renowned for its remarkable fat-burning properties without increasing appetite. It does not interfere with blood sugar or tissue growth (Heffernan 2001, Ng 2000). This peptide activates fat oxidation through mechanisms that are independent of hGH receptors. Laboratory studies on various animals and humans have demonstrated that AOD-9604 effectively promotes fat release from obese cells while minimizing new fat formation and enhancing fat oxidation. Notably, it excels in targeting abdominal fat reduction.

When focusing on fat loss, consider avoiding GHRP products (like GHRP-6 or GHRP-2) as they may increase hunger and cortisol levels. In contrast, AOD-9604 promotes fat loss without triggering appetite or cortisol spikes.

AOD 9604 Research:

Originally developed in the 1990s by Professor Frank Ng at Monash University in Australia, AOD-9604 (Advanced Obesity Drug) was designed to harness the fat-burning capabilities of human growth hormone (HGH) while avoiding muscle growth stimulation.

Recent studies have unveiled that AOD 9604 also possesses various regenerative qualities associated with growth hormone. Ongoing clinical trials are investigating its potential applications in osteoarthritis, hypercholesterolemia, and the repair of bone and cartilage.

Results from oral glucose tolerance tests indicate that, unlike HGH, AOD 9604 does not negatively affect carbohydrate metabolism. Notably, no anti-AOD 9604 antibodies were found in patients during antibody assays, and no serious adverse effects or withdrawal symptoms have been reported in connection with AOD 9604 usage in clinical studies.

Conclusion:

AOD 9604 has shown an impressive safety and tolerability profile, akin to that of a placebo, without the adverse effects commonly linked to full-length hGH treatments. With a stellar safety record, AOD 9604 has recently achieved Human GRAS status in the USA.